# Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer

> **NCT05387109** · PHASE4 · UNKNOWN · sponsor: **Tang-Du Hospital** · enrollment: 41 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** penpulimab combined with anlotinib

## Key facts

- **NCT ID:** NCT05387109
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-30
- **Primary completion:** 2023-04-20
- **Final completion:** 2024-04-20
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387109, "Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05387109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*